Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[What's new in oncodermatology?]

C Robert1

  • 1Chef du service de dermato-oncologie et INSERM U 981, Gustave-Roussy, université Paris-Sud, Le Kremlin-Bicêtre, France.

Annales De Dermatologie Et De Venereologie
|December 26, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.

ESMO open·2026
Same author

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Magnetic imaging under high pressure with a spin-based quantum sensor integrated in a van der Waals heterostructure.

Nature communications·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Impact of health simulation with OSCE on the acquisition of radiotherapy competencies by RTT students.

Radiography (London, England : 1995)·2025
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

This year in oncodermatology, immunotherapy research yielded mixed results. While epacadostat failed in melanoma trials, new combinations show promise for various skin cancers.

Area of Science:

  • Oncodermatology
  • Immunotherapy
  • Cancer Treatment

Background:

  • Recent advancements in oncodermatology have focused on immunotherapy and predictive biomarkers.
  • Immunotherapy, particularly targeting PD-1/PD-L1 pathways, has revolutionized cancer treatment.
  • Predictive biomarkers are crucial for optimizing treatment selection and patient outcomes.

Purpose of the Study:

  • To review significant developments in oncodermatology, focusing on immunotherapy advancements and treatment outcomes.
  • To highlight new therapeutic combinations and their efficacy in various skin cancers.
  • To discuss the impact of recent clinical trial results on current treatment paradigms.

Main Methods:

  • Review of published literature and clinical trial results in oncodermatology.
Keywords:
Adjuvant treatment of melanomaBiomarqueurs prédictifsCarcinome de MerkelCarcinome épidermoïdeMelanomaMerkel cell carcinomaMélanomePredictive biomarkersSquamous cell carcinomaTraitement adjuvant du mélanomeanti-PDL-1

Related Experiment Videos

  • Analysis of data from phase III trials and preliminary studies on novel drug combinations.
  • Evaluation of treatment efficacy, safety profiles, and biomarker research.

    • Main Results:

    • The IDO1 inhibitor epacadostat combined with pembrolizumab showed negative results in a phase III melanoma trial.
    • Promising preliminary results emerged from combinations of anti-PD1 therapies with innate immunity activators.
    • Encorafenib plus binimetinib demonstrated a favorable benefit/risk and safety profile for melanoma treatment.
    • Significant progress was observed in treating Merkel cell carcinoma and squamous cell carcinoma with anti-PD-L1 (avelumab) and anti-PD-1 (cemiplimab) therapies, respectively.

    Conclusions:

    • Immunotherapy continues to evolve in oncodermatology, with ongoing research into novel combinations and biomarkers.
    • While some approaches like epacadostat have faced setbacks, new therapeutic strategies offer significant potential.
    • Advances in targeted therapies and immune checkpoint inhibitors are improving outcomes for advanced skin cancers.